Global Liver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key takeaways for his business from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean and Global LIver Institute Vice President of Liver Programs Jeff McIntyre join Roger Green for 1:1 interviews exploring their key takeaways and strategic shifts resulting from the EASL Congress 2024, followed by a review of answers to a previous Question of the Week.
Roger Green speaks with Hepatology Key Opinion Leader and EASL Educational Councillor Sven Francque 90 minutes after the EASL Congress closed. The discussion covers Clinical Practice Guidelines, drug development and NITs.
In a conversation from May, 2023, patient advocates patient advocates Mike Betel, Tony Villiotti and Wayne Eskridge joined co-hosts Louise Campbell and Roger Green to share reactions to the Public Comments session of ICER’s report on MASH drugs obeticholic acid and resmetirom.
Roger Green conducts 1:1 interviews with Mike Betel, Louise Campbell and Sven Francque while they are at the EASL Congress 2024, discussing key issues related to MASLD
As the conversation wraps up, Jörn Schattenberg and Michelle Long discusses abstracts they will present at EASL Congress 2024, with Jörn focusing on new MASLD drug development and Michelle on an aggregation of studies sponsored by Novo Nordisk.
EASL Secretary General Aleksander Krag and our other guests, Hannes Hagstrom and Michelle Long, join Jörn Schattenberg and Roger Green to discuss MASLD-related highlights of EASL Congress 2024.
This week’s vault episode offers the last time Stephen Harrison presented results of a specific drug trial on the podcast.
This second conversation with Dimitar Tonev and Roger Green focus on some of the elements of Stephen’s personality that made him a role model for the entire community in Dimitar’s eyes.
